Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.10.23

ICH-M7 Services

Comprehensive ICH-M7 assessments for starting materials, intermediates, and final API

Sai Life Sciences offers comprehensive ICH-M7 services to help assess the potential risks of our customers' starting materials, intermediates, and final API for mutagenicity assessment.

As mandated in the ICH M7 guidelines, pharmaceutical companies are now required to assess, identify, and categorize their starting materials, intermediates and final API routes of synthesis and resulting impurities to limit the potential mutagenic risks to patients.

Sai’s ICH-M7 services include:

  • Comprehensive review of Routes Of Synthesis
  • Insilico assessment of compounds using Knowledge (Derek Nexus, Lhasa) and Statistical (TOPKAT, BIOVIA) approaches to assess genotoxicity and carcinogenicity alerts
  • Expert review and analysis to aid with decision making
  • Documentation of GTI assessment with justification (as per ICH-M7 classification)
  • In vitro and in vivo genotoxicity studies
  • Comprehensive review of all data, and recommendations for next steps
  • Support in identifying and implementing appropriate control strategies for mutagenic materials

Sai Life Sciences has handled over 100+ projects for its customers with their genotoxic impurity assessment and evaluation, helping them manage the risks associated with CMC regulatory concerns related to mutagenic risk.

To set up a meeting with our expert, email contact@sailife.com.

Share article

More News

2025.05.22

Innovator companies prefer to work with integrated partners: Krishna Kanumuri

In a recent interview with Global Business Reports, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, highlighted a growing industry trend: innovator companies are increasingly seeking integrated partners who can support them seamlessly from discovery through development and manufacturing. As an end-to-end CRDMO in India, Sai Life Sciences is well-positioned to meet this […]
Read more

2025.05.14

Sai Life Sciences Limited reports robust FY25 results

Revenue grows by 16%; Net Profit up 105% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, ContractResearch, Development and Manufacturing Organization (CRDMO) announced its financial results for the fourth quarter and full year ended March 31, 2025. Financial Performance: Particulars (₹ crores) FY25 FY24 YoY% Q4FY25 Q4FY24 YoY% Revenue from […]
Read more

2025.05.12

Sai Life Sciences wins Gold at CII Southern Region Awards

Sai Life Sciences has been honored with two Gold Awards at the CII Southern Region EHS Excellence Awards 2024, recognizing the company’s exemplary Environment, Health and Safety (EHS) initiatives across its sites in India. While the Integrated R&D Centre, Hyderabad, won Gold Award for EHS Excellence & Sector 2nd Topper in Pharmaceuticals & Healthcare, the […]
Read more

2025.05.02

Sai Life Sciences certified as a Great Place To Work

Sai Life Sciences has been officially certified as a Great Place To Work for 2025–26, a recognition based on feedback from its employees.The certification reflects the company’s culture and the experiences of its people, with positive responses in key areas such as Corporate Brand Image, Competence, Pride, Team, and Leadership Behaviour. Together, these highlight the […]
Read more

2025.05.02

Sai Life Sciences inks agreement with DHL Express to make logistics operations greener

Sai Life Sciences has inked an agreement with DHL Express to adopt its emission-reduced shipping solution — GoGreen Plus (GGP) — for its international logistics operations.To formalize the partnership, Sivaramakrishnan Chittor, CFO, Sai Life Sciences, signed an agreement with R.S. Subramanian, Senior Vice President – South Asia, DHL Express, on April 21, 2025.This collaboration will […]
Read more